Composition capable of lowering uric acid and preparation method thereof
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A composition and uric acid-lowering technology, applied in the direction of drug combination, effective ingredients of hydroxyl compounds, food science, etc., can solve the problems of easily inducing acute gout, toxic and side effects, and reducing curative effect, and achieve good development and application prospects and the effect of reducing uric acid
Pending Publication Date: 2021-01-08
SHIJI BIOLOGICAL MEDICINES WUXI CITY
View PDF5 Cites 3 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0003] At present, most of the chemical drugs for lowering uric acid are likely to cause toxic side effects. For example, the drug allopurinol, which inhibits the production of uric acid, has a high incidence of adverse reactions. About 2% of patients will experience allergic reactions, which may sometime
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0022] According to the above technical scheme, preferably, according to the ratio of parts by weight, it includes 50 parts of theaflavin, 55 parts of resveratrol, 50 parts of dihydromyricetin, 55 parts of theanine, 50 parts of cordycepin, and 120 parts of maltodextrin. parts, 110 parts of sucrose and 10 parts of magnesium stearate.
Embodiment 2
[0024] According to the above technical scheme, preferably, according to the ratio of parts by weight, it includes 60 parts of theaflavin, 60 parts of resveratrol, 60 parts of dihydromyricetin, 60 parts of theanine, 60 parts of cordycepin, and 130 parts of maltodextrin. 125 parts of sucrose and 15 parts of magnesium stearate.
Embodiment 3
[0026] According to the above technical scheme, preferably, according to the ratio of parts by weight, it includes 70 parts of theaflavin, 70 parts of resveratrol, 70 parts of dihydromyricetin, 65 parts of theanine, 60 parts of cordycepin, and 135 parts of maltodextrin. 120 parts, 120 parts of sucrose and 20 parts of magnesium stearate.
[0027] A preparation method for preparing a composition for reducing uric acid, comprising the following steps:
[0028] (1) Weighing theaflavins, resveratrol, dihydromyricetin, theanine, cordycepin, auxiliary material components, sweeteners and flow aids according to the ratio of parts by weight;
[0029] (2) Mix well and uniformly to make tablets, capsules or granules of the uric acid-lowering composition.
[0030] Tablet: the above-mentioned preferred formula combination (Example 1) through the verification of the effect example is fully stirred evenly, and tableted, and the above-mentioned ingredients are tableted and formed in an enviro...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention provides a composition capable of lowering uric acid and a preparation method thereof, and relates to the field of health food. The main functional components of the composition includetheaflavin, resveratrol, dihydromyricetin, theanine and cordycepin in set proportion. The composition mainly plays a role to lower the uric acid and resist to gout by inhibiting the activity of xanthine oxidase, adjusting related anionic transporter mRNA and protein expression levels and promoting uric acid excretion; the composition can also relieve the matrix degradation of chondrocyte after IL-1[beta] stimulation and reduce the expression of inflammatory factors, so that the symptoms of osteoarthritis and bone and joint pain can be relieved; and the composition is significant in efficacy, obvious in uric acid lowering, good in safety and convenient in taking, and has good development and application prospects.
Description
technical field [0001] The invention relates to the field of health food, in particular to a composition for reducing uric acid and a preparation method thereof. Background technique [0002] Gout is a disease caused by increased purine biosynthesis, excessive production of uric acid, or poor excretion of uric acid, resulting in elevated blood uric acid and deposition of urate crystals in the synovium, synovial bursa, cartilage and other tissues. Recurrent inflammatory disease, one of the most common types of arthritis in adults. The main goals of clinical drug treatment for gout are to control the acute attack of the disease, correct high uric acid, prevent arthritis recurrence and urate deposition, and protect kidney function. [0003] At present, most of the chemical drugs for lowering uric acid are likely to cause toxic side effects. For example, the drug allopurinol, which inhibits the production of uric acid, has a high incidence of adverse reactions. About 2% of pati...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more